Staging and follow-up of gastrointestinal tumors with PET/CT

Abdominal Imaging

Volumn 31, Issue 1, 2006, Pages 25-35

  Rosenbaum, S J ^a   Stergar, H ^a   Antoch, G ^a   Veit, P ^a   Bockisch, A ^a   Kuhl H ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Cancer; F 18 2 fluoro 2 deoxyglucose positron emission tomography; Gastroenterology; Positron emission tomography computed tomography

Indexed keywords

ACETIC ACID C 11; ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE; FLUORODEOXYGLUCOSE F 18; IMATINIB; OCTREOTIDE[TYROSINE 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID GA 68]; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; TRACER; UNCLASSIFIED DRUG;

BILE DUCT CARCINOMA; CANCER ADJUVANT THERAPY; CANCER STAGING; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIFFERENTIATION; DRUG ACCUMULATION; DRUG EFFECT; DRUG UPTAKE; DUODENUM CARCINOMA; ESOPHAGUS CARCINOMA; FOLLOW UP; GALLBLADDER CARCINOMA; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TUMOR; HEMIHEPATECTOMY; HUMAN; LIVER CELL CARCINOMA; LIVER METASTASIS; LIVER TUMOR; LYMPH NODE METASTASIS; LYMPHOMA; MORPHOLOGY; NEUROENDOCRINE TUMOR; NONHUMAN; ONCOLOGY; PANCREAS CARCINOMA; PATIENT CARE; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REVIEW; SMALL INTESTINE CARCINOMA; STOMACH CANCER;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; COLORECTAL NEOPLASMS; DIGESTIVE SYSTEM NEOPLASMS; DUODENAL NEOPLASMS; ESOPHAGEAL NEOPLASMS; FLUORODEOXYGLUCOSE F18; GALLBLADDER NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; LIVER NEOPLASMS; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; STOMACH NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 30544447307     PISSN: 09428925     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00261-005-0031-3     Document Type: Review

References (74)

1. Adams S, Baum R, Rink T, et al. (1998) Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med 25:79-83
2. Anderson CD, Rice MH, Pinson CW, et al. (2004) Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg 8:90-97
3. Antoch G, Kanja J, Bauer S, et al. (2004) Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 45:357-365
4. Antoch G, Saoudi N, Kuehl H, et al. (2004) Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol 1(22):4357-4368
5. Avril N (2004) GLUT1 expression in tissue and 18F-FDG uptake. J Nucl Med 45:930-932
6. Bastiaannet E, Groen H, Jager PL, et al. (2004) The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. Cancer Treat Rev 30:83-101
7. Beyer T, Antoch G, Blodgett T, et al. (2003) Dual-modality PET/CT imaging: the effect of respiratory motion on combined image quality in clinical oncology. Eur J Nucl Med Mol Imaging 30:588-596
8. Beyer T, Townsend DW, Brun T, et al. (2000) A combined PET/CT scanner for clinical oncology. J Nucl Med 41:1369-1379
9. Block MI, Sundaresan SR, Patterson GA (1997) Improvement in staging of esophageal cancer with the addition of positron emission tomography. Ann Thorac Surg 64:770-777
10. Bohm B, Voth M, Geoghegan J, et al. (2004) Impact of positron emission tomography on strategy in liver resection for primary and secondary liver tumors. J Cancer Res Clin Oncol 130:266-272
11. Burger I, Goerres GW, Schulthess GK, et al. (2002) PET/CT: diagnostic improvement in recurrent colorectal carcinoma compared to PET alone. Radiology 225(suppl P):242
12. Charron M, Beyer T, Bohnen NN, et al. (2000) Image analysis in patients with cancer studied with a combined PET and CT scanner. Clin Nucl Med 25:905-910
13. Chen YK, Kao CH, Liao AC, et al. (2003) Colorectal cancer screening in asymptomatic adults: the role of FDG PET scan. Anticancer Res 23(5b):4357-4361
14. Cohade C, Osman M, Leal J, Wahl R (2003) Direct comparison of 18F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med 44:1797-1803
15. Delbeke D, Rose DM, Chapman WC, et al. (1999) Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. J Nucl Med 40:1784-1791
16. De Potter T, Flamen P, Van Cutsem E, et al. (2002) Whole-body PET with FDG for the diagnosis of recurrent gastric cancer. Eur J Nucl Med Mol Imaging 29:525-529
17. Diederichs CG, Staib L, Vogel J, et al. (2000) Values and limitations of 18F-fluorodeoxyglucose-positron-emission tomography with preoperative evaluation of patients with pancreatic masses. Pancreas 20:109-116
18. Even-Sapir E, Parag Y, Lerman H, et al. (2004) Detection of recurrence in patients with rectal cancer: PET/CT after abdominoperineal or anterior resection. Radiology 232:815-822
19. Flamen P, Lerut A, Van Cutsem E (2000) Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 18:3202-3210
20. Flanagan FL, Dehdashti F, Siegel BA (1997) Staging of esophageal cancer with FDG-PET. AJR 168:417-424
21. Franke J, Rosenzweig S, Reinartz P, et al. (2000) Value of positron emission tomography (18F-FDG-PET) in the diagnosis of recurrent rectal cancer. Chirurg 71:80-85
22. Freudenberg LS, Antoch G, Beyer T, et al. (2003) Diagnosis of labia metastasis by F-18 FDG PET and CT fusion imaging in sarcoma follow-up. Clin Nucl Med 28:636-637
23. Fritscher-Ravens A, Bohuslavizki KH, Broering DC, et al. (2001) FDG PET in the diagnosis of hilar cholangiocarcinoma. Nucl Med Commun 22:1277-1285
24. Gayed I, Vu T, Iyer R, et al. (2004) The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med 45:17-21
25. Himeno S, Yasuda S, Shimada H (2002) Evaluation of esophageal cancer by positron emission tomography. Jpn J Clin Oncol 32:340-346
26. Ho CL, Yu SC, Yeung DW (2003) 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med 44:213-221
27. Hoffmann M, Kletter K, Diemling M, et al. (1999) Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. Ann Oncol 10:1185-1189
28. Hofmann M, Maecke H, Borner R, et al. (2001) Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med 28:1751-1757
29. Huebner RH, Park JE, Shepard JE, et al. (2000) A meta-analysis of the literature for whole body FDG-PET detection of recurrent colorectal cancer. J Nucl Med 41:1177-1189
30. Jadvar H, Fischman AJ (2001) Evaluation of pancreatic carcinoma with FDG PET. Abdom Imaging 26:254-259
31. Jones DR, Parker LA Jr, Detterbeck FC (1999) Inadequacy of computed tomography in assessing patients with esophageal carcinoma after induction chemoradiotherapy. Cancer 85:1026-1032
32. Kamel EM, Thumsirn M, Truninger K, et al. (2004) FDG Accumulations in the gastrointestinal tract in PET/CT: correlation with endoscopic and histopathologic results. J Nucl Med 45:1804-1810
33. Kato H, Miyazaki T, Nakajima M, et al. (2004) Value of positron emission tomography in the diagnosis of recurrent oesophageal carcinoma. Br J Surg 91:1004-1009
34. Kato H, Miyazaki T, Nakajima M, et al. (2005) The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma. Cancer 1(103):148-156
35. Keiding S, Hansen SB, Rasmussen HH, et al. (2000) Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography. Ugeskr Laeger 7(162):782-785
36. Khan MA, Combs CS, Brunt EM, et al. (2000) Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 32:792-797
37. Kim YJ, Yun M, Lee WJ, et al. (2003) Usefulness of 18F-FDG PET in intrahepatic cholangiocarcinoma. Eur J Nucl Med Mol Imaging 30:1467-1472
38. Kinkel K, Lu Y, Both M, et al. (2002) Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology 224:748-756
39. Kluge R, Schmidt F, Caca K, et al. (2001) Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer. Hepatology 33:1029-1035
40. Kole AC, Plukker JT, Nieweg OE (1998) Positron emission tomography for staging oesophageal and gastroesophageal malignancy. Br J Cancer 74:521-527
41. Kowalski J, Henze M, Schuhmacher J, et al. (2003) Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 5:42-48
42. Kuehle C, Veit P, Antoch G, et al. (2005) Contrast-enhanced dark lumen PET/CT and MR colonography in a rodent polyp model - initial results with histopathological correlation. AJR Am J Roentgenol 185:1045-1047
43. Kumar R, Xiu Y, Potenta S, et al. (2004) 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas. J Nucl Med 45:1796-17803
44. Lemke AJ, Niehues SM, Hosten N, et al. (2004) Retrospective digital image fusion of multidetector CT and 18F-FDG PET: clinical value in pancreatic lesions - a prospective study with 104 patients. J Nucl Med 45:1279-1286
45. Luketich JD, Schauer P, Meltzer CC (1997) The role of positron emission tomography in staging esophageal cancer. Ann Thorac Surg 64:765-769
46. 18F-FDG positron emission tomography in gastric and oesophageal carcinoma. Br J Radiol 72:525-529
47. Mertz HR, Sechopoulos P, Delbeke D, Leach SD (2000) EUS, PET, and CT scanning for evaluation of pancreatic adenocarcinoma. Gastrointest Endosc 52:367-371
48. Mochiki E, Kuwano H, Katoh H, et al. (2004) Evaluation of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer. World J Surg 28:247-253
49. Nakamoto Y, Chin BB, Cohade C, et al. (2004) PET/CT: artifacts caused by bowel motion. Nucl Med Commun 25:221-225
50. Ott K, Fink U, Becker K, et al. (2003) Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol 15(21):4604-4610
51. Ott K, Weber WA, Fink U, et al. (2003) Fluorodeoxyglucose-positron emission tomography in adenocarcinomas of the distal esophagus and cardia. World J Surg 27:1035-1039
52. Pereira PL, Clasen S, Boss A, et al. (2004) Radiofrequency ablation of liver metastases. Radiologe 44:347-357
53. Rankin SC, Taylor H, Cook GJR (1998) Computed tomography and positron emission tomography in the pre-operative staging of oesophageal carcinoma. Clin Radiol 53:659-665
54. Reske SN, Kotzerke J (2001) FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III," 21 July and 19 September 2000. Eur J Nucl Med 28:1707-1723
55. Rodriguez M, Ahlstrom H, Sundin A, et al. (1997) [18F] FDG PET in gastric non-Hodgkin's lymphoma. Acta Oncol 36:577-584
56. Rohren EM, Turkington TG, Coleman RE (2004) Clinical applications of PET in oncology. Radiology 2311:305-332
57. Rosa F, Meimarakis G, Stahl A, et al. (2004) Colorectal cancer patients before resection of hepatic metastases. Impact of (18) F-FDG PET on detection of extrahepatic disease. Nuklearmedizin 43:135-140
58. Schaefer NG, Hany TF, Taverna C, et al. (2004) Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging-do we need contrast-enhanced CT? Radiology 232:823-829
59. Schlag PM, Amthauer H, Stroszcynski C, Felix R (2001) Einfluß der Positronenemissionstomographie auf die chirurgische Therapieplanung beim colorectalen Rezidivtumor. Chirurg 72:995-1002
60. Sperti C, Pasquali C, Decet G, et al. (2005) F-18-fluorodeoxyglucose positron emission tomography in differentiating malignant from benign pancreatic cysts: a prospective study. J Gastrointest Surg 9:22-29
61. Stahl A, Ott K, Weber WA, et al. (2003) FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging 30:288-295
62. Sundin A, Eriksson B, Bergstrom M, et al. (2004) PET in the diagnosis of neuroendocrine tumors. Ann NY Acad Sci 1014:246-257
63. Stroobants S, Goeminne J, Seegers M, et al. (2003) 18FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 39:2012-2020
64. Tatlidil R, Jadvar H, Bading JR, Conti PS (2002) Incidental colonic fluorodeoxyglucose uptake: correlation with colonoscopic and histopathologic findings. Radiology 224:783-787
65. Truong MT, Erasmus JJ, Munden RF, et al. (2004) Focal FDG uptake in mediastinal brown fat mimicking malignancy: a potential pitfall resolved on PET/CT. AJR 183:1127-1132
66. Tutt ANJ, Plunkett TA, Barrington SF, Leslie MD (2004) The reole of positron emission tomography in the management of colorectal cancer. Colorectal Dis 6:2-9
67. van den Abbeele AD, Badawi RD, Cliche JP (2002) Response to imatinib mesylate (Gleevec) therapy in patients with advanced gastrointestinal stromal tumors (GIST) is demonstrated by F-18-FDG-PET prior to anatomic imaging with CT [abstract]. Radiology 225(suppl):424
68. van Oosterom AT, Judson I, Verweij J, et al. (2001) Safety and efficacy of imatinib (STI 571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358:1421-1423
69. Watanabe N, Hayashi S, Kato H, et al. (2004) FDG-PET imaging in duodenal cancer. Ann Nucl Med 18:351-353
70. Weber WA, Ott K, Becker K (2001) Prediction of response to preoperative chemotherapy in adenocarcinomas of esophagogastric junction by metabolic imaging. J Clin Oncol 19:3058-3065
71. Yeung HW, Macapinlac H, Karpeh M, et al. (1998) Accuracy of FDG-PET in gastric cancer. Preliminary experience. Clin Positron Imaging 1:213-221
72. Yeung HWD, Macapinlac HA, Mazumdar M (1999) FDG-PET in esophageal cancer: incremental value over computed tomography. Clin Positron Imaging 5:255-260
73. Yoshioka T, Yamaguchi K, Kubota K, et al. (2003) Evaluation of 18F-FDG PET in patients with a, metastatic, or recurrent gastric cancer. J Nucl Med 44:690-699
74. Lauren PA (1965) The two main histologic types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand 64:31-49